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Abstract During recent years, a ris-
ing incidence of invasive pulmonary
aspergillosis (IPA) in non-neutropenic
critically ill patients has been re-
ported. Critically ill patients are
prone to develop disturbances in
immunoregulation during their stay
in the ICU, which render them more
vulnerable for fungal infections. Risk
factors such as chronic obstructive
pulmonary disease (COPD), pro-
longed use of steroids, advanced liver
disease, chronic renal replacement
therapy, near-drowning and diabetes
mellitus have been described. Di-
agnosis of IPA may be difﬁcult and
obtaining histo- or cytopathological
demonstration of the fungus in order
to meet the gold standard for IPA is
not always feasible in these patients.
Laboratory markers used as a non-
invasive diagnostic tool, such as the
galactomannan antigen test (GM),
1,3-β-glucan, and Aspergillus PCR,
show varying results. Antifungal
therapy might be considered in pa-
tients with persistent pulmonary
infection who exhibit risk factors
together with positive cultures or
sequentially positive GM and As-
pergillus PCR in serum, in whom
voriconazole is the drug of choice.
The beneﬁt of combination anti-
fungal therapy lacks sufﬁcient ev-
idence so far, but this treatment
might be considered in patients with
breakthrough infections or refractory
disease.
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Introduction
Invasive pulmonary aspergillosis (IPA) has emerged as
an important cause of morbidity and mortality in patients
receiving intensive chemotherapy, allogeneic stem cell
transplantation, and solid organ transplantation. However,
during recent years, several reports have described a rising
incidence of IPA in critically ill patients admitted to
the intensive care unit (ICU), even in the absence of
an apparent predisposing immunodeﬁciency [1–6]. The
incidence of IPA in the ICU ranges from 0.3% to as
much as 5.8% [2, 3, 6] and it carries an overall mortal-
ity rate exceeding 80%, with an attributable mortality of
almost 20% [4, 5]. This high mortality is at least partially
related to difﬁculties in timely diagnosis, caused by insen-
sitive and non-speciﬁc clinical signs and lack of unequi-
vocal diagnostic criteria.
In this review, we will describe the pathophysiological
mechanisms and risk factors for IPA in non-neutropenic
critically ill patients, limitations and advances in the diag-
nostic process, and alterations in treatment with antifun-
gal therapy. A Medline/PubMed search was performed for
all articles about IPA in critically ill patients in relation to
risk factors, diagnosis and antifungal therapy. All publica-
tion types of human studies in the English language were
searched and an extraction of relevant articles was made
for the purpose of this narrative review.1695
Pathophysiological mechanisms and risk factors
Aspergillus spp. are opportunistic moulds that cause both
allergic and invasive syndromes. The genus Aspergillus
contains approximately 175 species, only a minority of
them have been associated with human disease. Infections
are caused mostly by Aspergillus fumigatus;n e x ti nl i n e
are Aspergillus ﬂavus, Aspergillus terreus, Aspergillus
niger andAspergillus nidulans [7]. Aspergillus is found
in soil, water, food, and in the air and grows on a wide
variety of organic material, such as decaying vegetation.
The conidia (spores) are easily aerosolised. The route of
transmission is by air. Although exposure is universal,
invasive infection occurs almost exclusively in immuno-
compromised individuals. Infections have frequently been
described in patients with haematological malignancies
and solid organ transplant recipients, but also in patients
undergoing chronic intermittent haemodialysis in whom
these infections were associated with hospital construction
and/or ventilation systems contaminated with Aspergillus
spp. [8]. Even hospital water is a frequently overlooked
source of nosocomial aspergillosis [9, 10].
Natural antifungal defence in humans is based on
normal mucosal barriers and an intact macrophage and
neutrophil function. Alveolar macrophages form the ﬁrst
line of defence against inhaled Aspergillus conidia that
reach the alveoli. Macrophages normally are capable of
killing the conidia and preventing germination, by releas-
ing cytokines such as tumour necrosis factor (TNF)-α and
macrophage inﬂammatory protein (MIP)-1α [11]. During
neutropenia, TNF-α and MIP-1α synthesis is reduced and
the conidia can germinate to form hyphae. T-cell mediated
acquired immunity also has an important role in protecting
against fungal infections, as Aspergillus antigens are able
to induceT-helper(Th)-1 andTh-2type reactivity[12,13].
Th-1 reactivity is displayed by an increase of interferon-γ
and interleukin (IL)-12 and has protective effects against
infection. In contrast, Th-2 reactivity is characterised
by production of IL-4 and IL-10 and leads to disease
progression, at least in a murine model of IPA [12, 14, 15].
Critically ill patients in ICU exhibit a complex change
in immune function characterised by deactivation of
macrophages and an altered cellular response due to the
severity of illness which is also termed “immunopar-
Risk factor Reference
COPD in combination with prolonged corticosteroid use [1, 24–26]
High-dose systemic corticosteroids >3weeks [2, 31, 33]
(e.g. prednisone equivalent >20mg/day)
Chronic renal failure with RRT [8, 35]
Liver cirrhosis/acute hepatic failure [2–4, 34]
Near-drowning [4, 36–38]
Diabetes mellitus [2, 3, 31, 33]
COPD, Chronic obstructive pulmonary disease; RRT, renal replacement therapy
Table 1 Risk factors for IPA in
non-neutropenic critically ill
patients in the ICU
alysis” [16, 17]. This immunologic derangement might
explain why Aspergillus infections are able to develop in
critically ill patients who do not display the predisposing
classical risk factors [17, 18]. Many other factors will
negatively inﬂuence the immune function during critical
illness, such as (acute) hyperglycaemia [19] and the use
of corticosteroids [20–23]. Corticosteroids have profound
effects on the distribution and function of neutrophils,
monocytes, and lymphocytes and they directly stimulate
the growth of Aspergillus fumigatus in vitro possibly via
sterol binding proteins in the fungus [21]. In particular
intravenous corticosteroids treatment in patients with
chronic obstructive pulmonary disease (COPD), is asso-
ciated with a rising incidence of IPA [1, 24–26]. Also
broad-spectrum antibiotics, which affect the distribution
of normal ﬂora, have been described as a risk factor [27].
However, not every critically ill patient in the ICU is at
risk for developing invasive fungal infections. Apparently,
other speciﬁc – patient-related – predisposing conditions
seem to be associated with the development of IPA, in
which COPD and other chronic lung disease [1–4, 28–32],
diabetes mellitus [2, 31, 33], acute liver failure/advanced
liver cirrhosis [2–4, 34], chronic renal failure [8, 35], and
near drowning [4, 36–38] have been described (Table1).
In these, mainly retrospective, studies a mean in-hospital
mortality of 80% was found in patients with highly
suspected or proven IPA in the presence of at least one of
these underlying conditions, despite antifungal therapy.
Remarkably, patients who were suspected to be colonised
only with Aspergillus spp. (i. e. no signs of pulmonary
infection) demonstrated even a high in-hospital mortality
rate [3, 31], which might suggest that colonisation should
be considered as a potentially important ﬁnding.
Diagnostic features
A few years ago, a consensus for standard deﬁnitions
and diagnosis for invasive fungal infections in immuno-
compromised patients with cancer and recipients of
haematopoietic stem cell transplants was established by
the European Organization for Research and Treatment
of Cancer and the Mycoses Study Group (EORTC/MSG)
in which three levels of probability for invasive fun-1696
gal infections are proposed: “proven”, “probable” and
“possible” [39]. However, these guidelines are intended
for use in clinical trials and for epidemiologic research
and, moreover, are focused on patients with classical
risk factors such as neutropenia, malignancies and after
haematopoietic stem cell transplantation, and it may not
be possible to extrapolate them to the non-neutropenic
critically ill patient.
The diagnosis of IPA in non-neutropenic critically
ill patients is difﬁcult because signs and symptoms are
non-speciﬁc, and the initiation of additional diagnostic
examinations is often delayed because of a low clinical
suspicion. For the timing of suspicion of IPA in these
patients, the combination of persistent or rapid developing
inﬁltrative abnormalities on thoracic imaging and/or
a persistent pulmonary infection despite broad spectrum
antibiotics accompanied by one or more predisposing
conditions (Table1) might be the moment for triggering
further diagnostic exploration. Although histopathological
evidence of IPA is deﬁned as the gold standard due to
a very high tropism for blood vessels [39], trans-bronchial
biopsy or surgical lung biopsy via mini-thoracotomy may
not justify the risk of this invasive procedure in critically
ill patients on mechanical ventilation with, sometimes,
severe bleeding diathesis. Therefore, the diagnostic pro-
cess will contain thoracic imaging and microbiological
examination by means of direct microscopy and culture
of sputum or broncho-alveolar lavage ﬂuid (BALF).
Excluding the possibility of contamination during the
pre-analytical phase of a sample, isolation of Aspergillus
spp. in the respiratory tract may represent three clini-
cal situations: (1) evidence of current disease, (2) true
colonisation, or (3) a marker for the future development of
invasive disease. In the immunocompetent host, cultures
of Aspergillus in respiratory secretions are usually a result
of colonisation [32]; in the immunocompromised host,
however, they may indicate invasive disease [6, 7, 39].
The positive predictive value of cultures in general is
as high as 80–90% [2, 6, 40], although in some groups
of patients (e.g. after lung transplantation) speciﬁcity is
much lower [41]. Sensitivity of cultures in the diagnosis
of IPA is poor [2, 6, 40]. Direct microscopic examination
of sputum or BAL, stained with speciﬁc ﬂuorescent
stain for chitin (a fungal cell wall component) is easy to
perform, rapid to read, and improves the sensitivity of
microbiological examination [40, 42]. Direct visualisation
of the hyphae makes it possible to discriminate between
septate (e.g. Aspergillus, Fusarium and Scedosporium)
and non-septate (e.g. Mucorales) moulds. Ubiquitous
moulds of the order Mucorales cause serious infection
in immunocompromised patients and, in contrast to
Aspergillus, Fusarium and Scedosporium spp., they are
not susceptible to voriconazole, which is an important
factor when choosing a pre-emptive antifungal drug. The
extra value of a positive culture is that growing of the
fungus enables identiﬁcation and susceptibility testing
to antifungal drugs. This is important in view of the
antifungal resistance of – for example – Aspergillus
fumigatus isolates to voriconazole [43]. Nonetheless,
reliance on microscopy and/or culture alone results in
substantial underdiagnosis due to the low sensitivity.
Fibre-bronchoscopy with inspection of the tracheo-
bronchial tree, sampling of deep airway secretions and
BAL can be helpful; the macroscopic ﬁnding of ulcerative
lesions and/or pseudomembranes together with a posi-
tive microscopy and/or culture is highly suggestive for
Aspergillus-related tracheobronchitis.
Chest computerised tomography (CT) has proved to
be an important tool for the diagnosis of IPA in neu-
tropenic, severely immunocompromised patients, even in
the absence of evident lesions on a conventional chest
X-ray. Radiological ﬁndings might include nodules with
rapid growth and/or cavitations. A ‘halo sign’ (a pul-
monary mass surrounded by a zone of lower attenuation
with ground-glass opaciﬁcation produced by adjacent
haemorrhage) and/or the ‘air crescent sign’ (crescentic
radiolucencies around a nodular area of consolidation)
may be present [44–50]. The frequency of the halo sign
in patients with IPA is relatively high in the early stages
of the disease, but becomes progressively lower with the
passage of time [51]. Combining the halo sign and the air
crescent sign, the sensitivity for IPA is more than 80%
as speciﬁcity reaches 60–98% [47]. However, thoracic
imaging in mechanically ventilated ICU patients is less
helpful due to many confounding factors such as atelec-
tasis and, sometimes major, pleural effusions. A lower
sensitivity (5–24%) of the halo sign and air crescent
sign in non-neutropenic patients has been reported in the
literature [3, 6, 52]. Due to the high tropism for blood
vessels, IPA might be complicated by localisations in
the central nervous system. Therefore, in patients with
documented or highly suspected IPA, CT scanning or
magnetic resonance imaging (MRI) of the brain should be
considered to exclude dissemination to the brain.
In the past decade, non-invasive diagnostic tests,
serological and molecular, have focused on the detec-
tion of surrogate markers for Aspergillus spp., such as
the galactomannan (GM) antigen, 1,3-β-glucan and the
detection of Aspergillus DNA by PCR. GM is a major
Aspergillus cell-wall component that is released during
the growth phase of the fungus, and detection of GM
would be indicative for invasive disease [53]. Many
studies have been done in order to investigate the value
of the commercial Platelia Aspergillus assay (BioRad™,
Marnes-La-Coquette, France) as a diagnostic tool for
IPA, but mainly in patients with haematological malig-
nancies [54–57]. The speciﬁcity of the GM assay for
diagnosing IPA is at least 85%, as demonstrated by these
studies, but the sensitivity of the assay varied considerably
between 29% and 100% depending on the cut-off value.
The most important ﬁnding of these studies was that in
around two-third of patients, circulating antigen could be1697
detected at a mean of 8 days before a probable diagnosis
was made by a combination of radiographic ﬁndings and
Aspergillus isolation [53,54]. In a recent meta-analysis,27
studies wereincludedregardingthe valueof theGM serum
assay for surveillance of IPA in high-risk patients. The
median sensitivity for proven cases was 71% (speciﬁcity
89%); for proven or probable cases, median sensitivity
and speciﬁcity were 61% and 93%, respectively [58].
Speciﬁcity increased to 95% using a cut-off value of
1.5 in cases with proven or probable IPA. Because GM
is a water-soluble carbohydrate, it can also be detected
in BALF. Although the Platelia ELISA (enzyme-linked
immunosorbentassay)is not validatedfor detectionof GM
in this ﬂuid, there is an increasing tendency to use these
samples for diagnosis of IPA. In small clinical studies
among patients with haematological malignancies and in
solid organ transplant recipients, the sensitivity of the GM
EIA (enzyme immuno-assay) applied to BALF ranges
from 85% to 100% with a high index cut-off (> 1.5)
to deﬁne positivity [59–62]. However, there are several
clinical circumstances that might inﬂuence the diagnostic
performance of the GM antigen test in either serum or
BALF. First, the false-positive reactivity which might be
caused by gastro-intestinal translocation of fungal GM
from contaminatedfood or drink, as demonstratedin small
children [63], and the use of the intravenous antibiotics
piperacillin–tazobactam and amoxicillin–clavulanic acid,
which is associated with serum ELISA reactivity in
patients without evidence of IPA [64–67]. Second, an
important factor that affects the release of GM antigens
is antifungal drug therapy. Different animal and human
studies have shown decreased sensitivity of the GM assay
when (prophylactic) antifungal drugs were used [63, 68,
69]. In several prospective studies that assessed the perfor-
mance of antigen detection, patients received antifungal
prophylaxis with itraconazole, which might have a signiﬁ-
cant effect on the sensitivity of the assay [53, 54]. Third,
when the Platelia Aspergillus ELISA kit was launched in
Europe about a decade ago, another cut-off serum ratio
was recommended than at present. Over the past years,
several studies suggested lower cut-off values, ranging
from 0.5 to 1 [39, 53, 54, 70–72].It is clear that alterations
in cut-off level will change the performance of the assay.
Finally, the studies show that monitoring GM levels is
crucial in order to diagnose (and eventually monitor
treatment outcome) correctly, which means that the assay
has to be performed twice weekly, preferably on receipt
of the specimen. In critically ill patients without classical
risk factors for IPA, the diagnostic value of the GM assay
has been investigated only in one retrospective study and
demonstrated a sensitivity of only 53% in patients with
proven or probable IPA (cut-off value 1.0) [3]. Thus, it
has to be stressed that the available data from patients
with (haematological) malignancies and after solid organ
transplantation can not be extrapolated to the critically ill
patient in general. In the meantime, due to lack of more
reliable, non-invasivediagnostic tests, the GM assay could
be used as an additive tool in the diagnostic work-up
of IPA.
The 1,3-β-glucan is a cell wall component of many ﬁl-
amentous fungi and yeasts, including Aspergillus spp. and
Candida spp. Reproducible assay results, with high speci-
ﬁcity and a high positive predictive value, demonstrated
that use of an assay to detect serum 1,3-β-glucan derived
from fungal cell walls is a useful diagnostic adjunct for
invasive fungal infection [73]. In addition, false-positive
tests have been found in patients after haemodialysis,
cardiopulmonary bypass surgery, high-dose immunoglob-
ulin treatment, and after exposure to glucan-containing
gauze [33]. Furthermore, in a recent small prospective
study among ICU patients, serum glucan levels did not
appear to be speciﬁc for fungal infections, as serum glucan
levels were also elevated in bacterial infections [74].
Hence, the usefulness of 1,3-β-glucan in the diagnosis of
IPA has to be further evaluated.
Ampliﬁcation of nucleic acid by PCR technology for
the diagnosis of IPA is being increasingly studied. It can
be applied to serum and BAL specimens [75–79]. Experi-
ence is limited to patients with haematological malignan-
cies. White et al. evaluated the performance of a real-time
PCR in whole blood in a group of patients with haemato-
logical malignancies and showed sensitivity of 92.3% and
speciﬁcity of 94.6% for the diagnosis of IPA with good
agreement of the GM ELISA [80]. They concluded that
a negative PCR obtained twice weekly allowed a wait-
and-seeapproachconcerningstarting antifungaltreatment.
However, comparable to the GM antigen test, there are
a number of factors that potentially have an impact upon
the clinical sensitivity of PCR. The magnitude of the quan-
titative PCR signal falls with antifungal therapy, thereby
causing false-negative PCR results [81] while the (tran-
sient) colonising presence of Aspergillus in the respira-
tory tract may suggest a low positive predictive value [78].
Furthermore, patients at risk for IPA are often prescribed
a multitude of drugs and ﬂuids, all of which may act as
non-speciﬁc inhibitors of the PCR. For example, anticoag-
ulants inhibit PCR, thereby limiting its sensitivity [82].
One might conclude that the use of GM antigen
test, 1,3-β-glucan, and Aspergillus PCR as serological
and molecular markers cannot be advocated for routine
use in critically ill patients, and caution is warranted
in the interpretation of positive test results in patients
without a clinical suspicion of pulmonary infection as
well as negative test results in patients with persisting
pneumonia. However, the ﬁnding of sequentially positive
GM tests in serum or BALF – using higher cut-off values
– together with a positive Aspergillus PCR, in a patient
with persisting pulmonary infection who carries one or
more risk factors, is highly indicative for IPA and might
justify treatment with antifungal therapy.1698
Antifungal therapy
There have been important developments in antifungal
drugs in the past few years, although amphotericin B
deoxycholate has been the standard therapy for IPA for
decades. However, multiple studies have now established
not only its lack of efﬁcacy due to an increasing antifungal
resistance but also demonstrated unacceptable toxicity
of this compound, in particular nephrotoxicity [83, 84].
Continuous infusion of amphotericin B deoxycholate over
24h may reduce its nephrotoxicity [85, 86], although
the efﬁcacy may be reduced due to lower peak serum
levels [87]. The use of lipid formulations may also reduce
toxicity and have been studied extensively for empirical
use in febrile neutropenia with the same efﬁcacy rate
as conventional amphotericin B [88]. However, lipid
formulations are more expensive, and the initial use of
higher doses does not improve efﬁcacy and is associated
with greater toxicity than lower doses, which suggests that
high doses may not be routinely warranted.
Among the triazoles, itraconazole has activity against
Aspergillus, but its clinical utility in critically ill pa-
tients with IPA has been limited by drug interactions and
toxicity as well as erratic bioavailability of the oral suspen-
sions [89]. Furthermore, strains of Aspergillus fumigatus
resistant to itraconazole have already been described [90].
A large multicentre randomised trial established that
voriconazole provides higher response rates and better
survival than amphotericin B in the treatment of “probable
or proven” IPA among patients with haematological
diseases with fewer drug-related adverse events [91].
As a result of this study, voriconazole is increasingly
recommended as initial therapy for IPA [92]. Voriconazole
is available for intravenous and oral use. It is rapidly
absorbed within 2 h after oral administration and the oral
bioavailability is over 90% [93]. Clearance is hepatic via
N-oxidation by the hepatic cytochromeP450 (CYP) isoen-
zymes, CYP2C19, CYP2C9 and CYP3A4 [93], which
makes the potential for drug interactions considerable. For
instance, voriconazole considerably reduces the clearance
of intravenous midazolam [94], and fatal interactions
with highly active antiretroviral therapy (HAART) have
been described [95]. As voriconazole has limited aqueous
solubility, the intravenous form includes the solvent
vehicle sulfobutylether beta cyclodextrinsodium [96]. The
clearance of sulfobutylether beta cyclodextrin sodium is
linearly related to creatinine clearance and accumulation
has been described in subjects with moderate to severe
renal impairment [96], although in animal experiments
the frequency of acute toxicity of sulfobutylether beta
cyclodextrin sodium is low. Target organs for toxic
effects are the kidney and liver, causing obstruction of
renal tubules and necrosis in the liver respectively [96].
Because of this potential toxicity, it is recommended
to treat patients with moderate to severe renal failure
and who are on renal replacement therapy only with
the oral form of voriconazole, if feasible. However, in
critically ill patients safe oral administration of drugs
is difﬁcult to accomplish as, for instance, gastric reﬂux,
gastro-intestinal bleeding and impaired function of the
intestine are frequentco-morbidities,leading to potentially
insufﬁcient intestinal absorption of the drug. Furthermore,
it is important to recognise that some patients may have
inadequate levels of the oral drug, particularly if a stan-
dard dose of 200mg twice daily is used rather than the
recommended 4mg/kg twice daily dose which has been
studied for the intravenous formulation [97]. At present,
no clinical data are available regarding the bioavailability
of the oral form of voriconazole in critically ill patients.
It might be considered that the fear of potential adverse
effects from intravenous solutions does not justify the
risk of insufﬁcient treatment by oral solutions. Moreover,
limited clinical data showed no obvioustoxicity in patients
undergoing intermittent haemodialysis who were treated
with daily 400–800mg of intravenousvoriconazoleduring
2 weeks [96], and the pharmacokinetics of voriconazole
appears not to be affected by continuous renal replace-
ment therapy (CRRT). On the basis of pharmacokinetics,
dose reduction is not recommended in patients receiving
CRRT [98, 99]. Regarding the efﬁcacy of voriconazole,
there is a potential concern with (long-term) voriconazole
therapy as occasional breakthrough infections with yeasts
and moulds, with decreased susceptibility to voriconazole,
have been reported [43, 100, 101].
Posaconazole is a promising new triazole with broad-
spectrum antifungal proﬁle and has shown activity for
salvage treatment of IPA in patients who are refractory
to or intolerant of conventional therapy. A recent mul-
ticentre, prospective study among haematological and
non-neutropenicpatientswithrefractoryIPA demonstrated
a 42% overall success rate for posaconazole recipients
versus 26% for control subjects [102]. Posaconazole is,
however, only available for oral administration, which
makes it probably less applicable in critically ill patients
who are susceptible to impaired drug absorption in the
digestive tract.
Echinocandins are a novel class of parenterally
administered semi-synthetic lipopeptides with a pathogen-
speciﬁc mechanism for non-competitive inhibition of
biosynthesis of the fungus cell-wall enzyme complex 1,3-
β-D-glucan [103]. The echinocandins have documented
in vivo activity against Candida spp. and Aspergillus
spp. At present, there are three approved echinocandins,
caspofungin, anidulafungin and micafungin, of which
particularly caspofungin has demonstrated efﬁcacy for
the treatment of IPA. The ﬁrst clinical trial to document
the efﬁcacy of caspofungin was among patients with
“proven or probable” IPA who had treatment failure with
(liposomal) amphotericin B, itraconazole or voriconazole,
or who were intolerant to these antifungal drugs [104].
Caspofungin seems to be as effective as and generally
better tolerated than liposomal amphotericin B when given1699
Table 2 Treatment options with antifungal drugs for IPA in critically ill patients in the ICU
Setting First choice Alternatives
Primary therapy of IPA Voriconazole 6mg/kg q12h i.v. on day1, Liposomal amphotericin B 3-5mg/kg/day i.v.
then4mg/kgq12hi.v .
or or
Voriconazole 400mg q12h oral on day1, Amphotericin B deoxycholate 1mg/kg/day i.v.
then 200mg q12h oral a
or
Caspofungin 70mg i.v. on day1, then 50mg/day i.v. b
a Oral administration is recommended only in patients with intact intestinal absorption; b In patients with moderate to severe hepatic failure,
dose reduction is recommended to 35mg/day i.v.
as empirical antifungal therapy in patients with persistent
fever and neutropenia [105]. However, prospective ran-
domised clinical trials aimed at the treatment of IPA in
(non-neutropenic) critically ill patients are lacking.
In general, there is no conclusive evidence that
extended-spectrum triazoles are superior to echinocandins
or polyenes, or vice versa, for monotherapy of IPA in ICU
patients. We need prospective randomised controlled trials
to solve this issue in critically ill patients. Table 2 gives an
overview of treatment options with antifungal drugs for
IPA.
Combination therapy
Because the efﬁcacy of antifungal therapy for IPA is poor,
with more than 50% of all patients experiencing failure of
ﬁrst-line therapies [106, 107] empirical administration of
combination antifungal regiments for proven or probable
IPA may be an important strategy to improve outcome.
Theoretically, there are several foreseeable advantages
of combination therapy, such as a widened spectrum and
potency of drug reactivity, more rapid antifungal effect,
synergy, and a reduced risk of antifungal resistance [108].
The available antifungal drugs target four different cell
functions: cell membrane integrity (polyenes), ergosterol
biosynthesis (azoles, allylamines), DNA synthesis (pyrim-
idine analogues) and cell-wall integrity (echinocandins).
Although antifungaldrugs are targeted againstspeciﬁc cell
functions, many drugs also have pleiotropic effects that
may inhibit other elements of fungal homeostasis [108].
For instance, azoles inhibit many cytochrome-dependent
enzymes of the fungal respiration chain and ampho-
tericin B generates oxidative species that damage fungal
mitochondrial function and enhance macrophage fungal
killing [109]. These subtle effects could be enhanced
when one antifungal is applied together with a second
drug, resulting in synergy. Conversely, the combination
could act antagonistically, e.g. when one antifungal agent
affects the targets of the other one.
Only a few clinical studies with small numbers of
patients have tried to address the need for combination an-
tifungal therapy [110–113] . These studies have important
limitations because they lack a control group and because
of many other uncontrolled factors including the choice
of combination, the duration of therapy, concomitant
antibacterial or antiviral treatment, the lack of adequate
follow-up to estimate relapses, and no discrimination
between primary and sequential therapy. Results from
those studies should therefore be viewed with caution.
Large, adequately powered, prospective clinical trials are
needed but they might be difﬁcult to perform because of
inadequate enrolment, differences in providing beneﬁts,
difﬁculty in documenting fungal infection, controversy
regarding endpoints, the lack of surrogate markers to
correlate in-vitro evidence to outcome prognosis, and
the associated costs [114]. Nevertheless, combination
antifungal therapy might be considered for certain clinical
conditions such as refractory disease or breakthrough
infections [115, 116].
Conclusion
Recent data indicate that IPA may be an underestimated
opportunistic fungal infection in critically ill patients,
even in the absence of severe pre-existent immunological
disorders, and carries a high mortality rate. A decrease
in immune function or dysregulation of the immune
system due to the severity of illness, together with speciﬁc
underlying risk factors such as COPD, diabetes mellitus,
chronic renal replacement therapy, advanced liver disease,
and long-term use of steroids, might explain the relatively
high occurrence of IPA among these patients. The high
mortality rate is partially related to difﬁculties in timely
diagnosis because of non-speciﬁc signs and symptoms,
low clinical suspicion, and time delay due to high risks
for invasive procedures to obtain histopathological evi-
dence for diagnosing IPA. The presence of a persistent
pulmonary infection despite broad-spectrum antibiotics or
abnormal thoracic imaging by CT scanning together with
one of these risk factors should trigger further diagnostic
exploration by collecting respiratory secretions and/or
laboratory markers. Meeting the gold standard alone1700
should not be the threshold for starting antifungal therapy,
considering the high mortality rate. Invasive infection
in patients with negative cultures might be supported
by positive serological and molecular markers such as
galactomannan antigen testing and Aspergillus PCR,
which requires at least two sequentially positive samples.
Antifungal therapy might be considered when persistent
pneumonia with positive cultures for Aspergillus spp.
or sequentially positive GM and Aspergillus PCR are
present, accompanied with one of those risk factors for
which voriconazole appears to be the ﬁrst-line treatment.
Combination therapy might be considered in breakthrough
infections with moulds or yeasts or in refractory disease,
although clear evidence is lacking.
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